Psoriatic Arthritis – Pipeline Review, H1 2013
Summary
Global Markets Direct’s, ''Psoriatic Arthritis - Pipeline Review, H1 2013'', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic
|
$ 2000
|
|
|
Rheumatoid Arthritis – Pipeline Review, H1 2013
Summary
Global Markets Direct’s, ''Rheumatoid Arthritis - Pipeline Review, H1 2013'', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeut
|
$ 2500
|
|
|
Gouty Arthritis (Gout) – Pipeline Review, H1 2013
Summary
Global Markets Direct’s, ''Gouty Arthritis (Gout) - Pipeline Review, H1 2013'', provides an overview of the indication’s therapeutic pipeline. This report provides information on the thera
|
$ 2000
|
|
|
Global Markets Direct’s, 'Arthritis Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Arthritis, complete with latest u...
|
$ 2000
|
|
|
GBI Research, the leading business intelligence provider, has released its latest research, Monoclonal Antibodies Market in Rheumatoid Arthritis to 2018 - Market Characterized by Large and Diversified Pipeline and Low Threat of Biosimilar S...
|
$ 3500
|
|
|
Rheumatoid Arthritis Partnering 2007-2013 report provides understanding and access to the rheumatoid arthritis partnering deals and agreements entered into by the worlds leading healthcare companies.
•Trends in rheumatoid arthritis partnering deals
|
$ 1695
|
|
|
Arthritis Partnering 2007-2013 report provides understanding and access to the arthritis partnering deals and agreements entered into by the worlds leading healthcare companies.
•Trends in arthritis partnering deals
•Top arthritis deals by value
|
$ 1695
|
|
|
PharmaPoint: Rheumatoid Arthritis - United States Drug Forecast and Market Analysis Event-Driven Update
Summary
GlobalData has released its new Country report, “PharmaPoint: Rheumatoid Arthritis - United States Drug Forecast and Market Analysis
|
$ 4995
|
|
|
GlobalData has released its pharma report, PharmaPoint: Rheumatoid Arthritis - Current and Future Players. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Rheumatoid...
|
$ 2995
|
|
|
Enbrel (Rheumatoid Arthritis) Forecast and Market Analysis
Summary
GlobalData has released its new PharmaPoint Drug Evaluation report, Enbrel (Rheumatoid Arthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with the
|
$ 3495
|
|
|
PharmaPoint: Rheumatoid Arthritis - United Kingdom Drug Forecast and Market Analysis Event-Driven Update
Summary
GlobalData has released its new Country report, “PharmaPoint: Rheumatoid Arthritis - United Kingdom Drug Forecast and Market Analys
|
$ 4995
|
|
|
Humira (Rheumatoid Arthritis) Forecast and Market Analysis
Summary
GlobalData has released its new PharmaPoint Drug Evaluation report, Humira (Rheumatoid Arthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with the
|
$ 3495
|
|
|
PharmaPoint: Rheumatoid Arthritis - France Drug Forecast and Market Analysis Event-Driven Update
Summary
GlobalData has released its new Country report, “PharmaPoint: Rheumatoid Arthritis - France Drug Forecast and Market Analysis Event-Driven
|
$ 4995
|
|
|
Remicade (Rheumatoid Arthritis) Forecast and Market Analysis
Summary
GlobalData has released its new PharmaPoint Drug Evaluation report, Remicade (Rheumatoid Arthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with
|
$ 3495
|
|
|
PharmaPoint: Rheumatoid Arthritis - Germany Drug Forecast and Market Analysis Event-Driven Update
Summary
GlobalData has released its new Country report, “PharmaPoint: Rheumatoid Arthritis - Germany Drug Forecast and Market Analysis Event-Drive
|
$ 4995
|
|
|
Simponi (Rheumatoid Arthritis) Forecast and Market Analysis
Summary
GlobalData has released its new PharmaPoint Drug Evaluation report, Simponi (Rheumatoid Arthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with t
|
$ 3495
|
|
|
PharmaPoint: Rheumatoid Arthritis - Spain Drug Forecast and Market Analysis Event-Driven Update
Summary
GlobalData has released its new Country report, “PharmaPoint: Rheumatoid Arthritis - Spain Drug Forecast and Market Analysis Event-Driven Up
|
$ 4995
|
|
|
PharmaPoint: Rheumatoid Arthritis - Italy Drug Forecast and Market Analysis Event-Driven Update
Summary
GlobalData has released its new Country report, “PharmaPoint: Rheumatoid Arthritis - Italy Drug Forecast and Market Analysis Event-Driven Up
|
$ 4995
|
|
|
PharmaPoint: Rheumatoid Arthritis - Japan Drug Forecast and Market Analysis Event-Driven Update
Summary
GlobalData has released its new Country report, “PharmaPoint: Rheumatoid Arthritis - Japan Drug Forecast and Market Analysis Event-Driven Up
|
$ 4995
|
|
|
PharmaPoint: Rheumatoid Arthritis - China Drug Forecast and Market Analysis Event-Driven Update
Summary
GlobalData has released its new Country report, “PharmaPoint: Rheumatoid Arthritis - China Drug Forecast and Market Analysis Event-Driven Up
|
$ 4995
|
|
|